Charts of the Day: Incyte, WD-40, Gain Capital Holdings

Incyte's experimental melanoma treatment fails to meet its phase 3 primary endpoint; WD-40 beat on earnings, missed on revenue and sales growth; Gain Capital Holdings to continue rollout of its cryptocurrency offerings

What to read next

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes